June 2, 2021

Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib have been wonderfully effective drugs for treating chronic lymphocytic leukemia (CLL). However, on their own they must be taken continuously and do not produce deep enough remissions to warrant stopping treatment.